{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Scinai Immunotherapeutics Ltd."},"Symbol":{"label":"Symbol","value":"SCNI"},"Address":{"label":"Address","value":"HADASSAH EIN KEREM CAMPUS,JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM, 74036, Israel"},"Phone":{"label":"Phone","value":"+972 89302529"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Middle East"},"CompanyDescription":{"label":"Company Description","value":"BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic."},"CompanyUrl":{"label":"Company Url","value":"https://www.biondvax.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Amir Reichman","title":"Chief Executive Officer & Director"},{"name":"Dalit Weinstein Fischer","title":"Chief Technology Officer"},{"name":"Elad Mark","title":"Chief Operating Officer"},{"name":"Tamar Ben-Yedidia","title":"Chief Science Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}